View ValuationCalithera Biosciences 将来の成長Future 基準チェック /06現在、 Calithera Biosciencesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Price Target Changed • Nov 16Price target decreased to US$12.36Down from US$30.00, the current price target is an average from 3 analysts. New target price is 419% above last closing price of US$2.38. Stock is down 88% over the past year. The company is forecast to post a net loss per share of US$5.24 next year compared to a net loss per share of US$31.16 last year.Price Target Changed • Apr 27Price target decreased to US$2.38Down from US$2.88, the current price target is an average from 4 analysts. New target price is 850% above last closing price of US$0.25. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$0.67 next year compared to a net loss per share of US$1.56 last year.Price Target Changed • Jan 05Price target lowered to US$10.10Down from US$11.50, the current price target is an average from 4 analysts. The new target price is 271% above the current share price of US$2.72. As of last close, the stock is down 47% over the past year.すべての更新を表示Recent updatesお知らせ • Jun 15Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s DiseaseCalithera Biosciences, Inc. announced the commercial launch of its next generation system: the Cala kIQ System, the first and only FDA-cleared wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease. The Cala kIQ System delivers Cala TAPS (Transcutaneous Afferent Patterned Stimulation) therapy, which is validated by large clinical studies and real-world evidence demonstrating clinically meaningful tremor reduction and improvement in activities of daily living (ADLs). The Cala kIQ System empowers patients and physicians by providing an on-demand, comfortable, at-home therapy for ease of use and management of action hand tremors. This type of tremor occurs when the patient undergoes intentional movement or posture. Millions of people across the US live with essential tremor or Parkinson’s disease, and diagnoses continue to rise. Treatment options for these conditions have historically been medications or, in more severe cases – surgery. The Cala kIQ System with TAPS therapy offers a non-invasive, non-pharmacologic solution with minimal side effects. The Cala kIQ System measures each patient's unique tremor physiology and individualizes a stimulation pattern for tremor relief. The system is designed to be easy to use for patients and easy to manage for clinicians. Therapy is on-demand for patients and delivered via a wrist-worn wearable. Designed with patients in mind for comfort and usability, the system also offers online data insights through the MyCala.com patient portal. Patients can see their therapy session results over time and choose to share with their providers to adjust treatment plans. Cala is committed to providing patients expanded access to Cala TAPS therapy. Cala is a contracted provider with major national and regional health plans for essential tremor including both commercial and Medical Advantage members. The Cala kIQ System is covered by the Veterans Affairs (VA) Health System at no cost to VA beneficiaries. Cala is working to secure additional coverage and reimbursement for the new breakthrough designated Parkinson's disease indication for the Cala kIQ System.お知らせ • Feb 03Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from NASDAQ Composite IndexCalithera Biosciences, Inc. will be removed from the NASDAQ Composite Index.お知らせ • Jan 26Calithera Biosciences Board Approves Dissolution and LiquidationOn January 9, 2023, Calithera Biosciences, Inc. announced that its Board of Directors had unanimously approved the dissolution and liquidation of Calithera Biosciences pursuant to a plan of complete liquidation and dissolution, subject to stockholder approval. The company also announced, that in order to reduce costs and in connection with the planned dissolution, the company was discontinuing all clinical development programs and reducingour workforce, including the termination of most employees by the end of the first quarter. In light of planned dissolution, on January 24, 2023, the company received written notice from The Nasdaq Stock Market LLC, or Nasdaq, advising the company that based upon Nasdaq's review and pursuant to Listing Rule 5101, Nasdaq believes that the company is a public shell," and that the continued listing of the company's securities is no longer warranted. The company will not appeal Nasdaq's determination. Therefore, the company expects, based on Nasdaq's written notice, that the trading of the company's common stock will be suspended as of the opening of business on February 2, 2023, and that Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove the company's common stock from listing and registration on Nasdaq.お知らせ • Jan 10+ 2 more updatesCalithera Biosciences, Inc. Announces Executive DeparturesCalithera Biosciences, Inc. announced that in connection with the approval of the reduction-in-force, Eric Sjogren, Ph.D. company's Senior Vice President, Drug Discovery will be leaving Calithera Biosciences on February 3, 2023. Dr. Sjogren will be entitled to certain severance payments and the continuation of health benefits pursuant to the Calithera Biosciences, Inc. In connection with the reduction-in-force and wind up of company's operations, Susan M. Molineaux, Ph.D., company's President will also be leaving Calithera Biosciences as of future date to be determined, and will be entitled to certain severance payments and the continuation of health benefits pursuant to the Calithera Biosciences, Inc.Price Target Changed • Nov 16Price target decreased to US$12.36Down from US$30.00, the current price target is an average from 3 analysts. New target price is 419% above last closing price of US$2.38. Stock is down 88% over the past year. The company is forecast to post a net loss per share of US$5.24 next year compared to a net loss per share of US$31.16 last year.Seeking Alpha • Oct 03Calithera gains 16% as FDA awards Fast Track status for lung cancer candidateCalithera Biosciences, Inc. (NASDAQ:CALA) added ~16% pre-market Monday after the oncology-focused biotech announced that the FDA issued the Fast Track designation for sapanisertib as a treatment for adults with a certain type of lung cancer. Specifically, the FDA has offered the designation for sapanisertib to treat adults with unresectable or metastatic squamous non-small cell lung cancer with a particular genetic mutation in tumors and who have previously received chemotherapy and immune checkpoint inhibitors. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. If certain criteria are met, such programs will also be able to win the Accelerated Approval and Priority Review, enabling the treatments to reach patients sooner. In July, CALA announced that the patient recruitment started in Phase 2 for sapanisertib (CB-228), designed to study the candidate in certain patients with squamous non-small cell lung cancer.Seeking Alpha • Aug 29Calithera rises 8% after HC Wainwright upgrades rating to buyCalithera Biosciences (NASDAQ:CALA) is trading ~8% higher after HC Wainwright upgrades rating to Buy to Neutral, with an $8 price target. HC Wainwright analyst Swayampakula Ramakant believes the company has sufficient cash to fund operations into Q2 of 2023. The company had cash and cash equivalents of $41.8M at June 30. Calithera has two ongoing clinical development programs that are expected to provide data updates in Q1 of 2023, Ramakanth tells investors in a research note. If positive, both drugs could be evaluated in registrational studies to achieve accelerated FDA approval, says the analyst. He estimates Calithera to achieve risk-adjusted revenues of $111M by 2030. (CALA) is down ~74% YTD.分析記事 • Aug 17Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Price Target Changed • Apr 27Price target decreased to US$2.38Down from US$2.88, the current price target is an average from 4 analysts. New target price is 850% above last closing price of US$0.25. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$0.67 next year compared to a net loss per share of US$1.56 last year.分析記事 • Dec 17We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Recent Insider Transactions • Nov 12Independent Director recently bought US$172k worth of stockOn the 10th of November, Jonathan Drachman bought around 200k shares on-market at roughly US$0.86 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$257k more in shares than they have sold in the last 12 months.分析記事 • Aug 27We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Aug 03The Upcoming Calithera Cystic Fibrosis Data Could Be SignificantCalithera is guiding for the market to expect what we believe will be a key data read-out from its ongoing CB-280 study involving Cystic Fibrosis. We anticipate full data set to read out in early October at the North American Cystic Fibrosis Conference. A positive read-out here could see a very strong stock appreciation, which currently the market may be overlooking.分析記事 • May 02Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Executive Departure • Apr 06Chief Business Officer has left the companyOn the 2nd of April, Curtis Hecht's tenure as Chief Business Officer ended after 2.2 years in the role. We don't have any record of a personal shareholding under Curtis' name. Curtis is the only executive to leave the company over the last 12 months.分析記事 • Mar 10What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?If you want to know who really controls Calithera Biosciences, Inc. ( NASDAQ:CALA ), then you'll have to look at the...分析記事 • Jan 17Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value EstimateIn this article we are going to estimate the intrinsic value of Calithera Biosciences, Inc. ( NASDAQ:CALA ) by taking...Is New 90 Day High Low • Jan 05New 90-day low: US$2.72The company is down 25% from its price of US$3.61 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$23.10 per share.Price Target Changed • Jan 05Price target lowered to US$10.10Down from US$11.50, the current price target is an average from 4 analysts. The new target price is 271% above the current share price of US$2.72. As of last close, the stock is down 47% over the past year.分析記事 • Dec 13Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Is New 90 Day High Low • Dec 11New 90-day high: US$5.03The company is up 39% from its price of US$3.63 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$17.34 per share.Is New 90 Day High Low • Nov 13New 90-day high: US$4.60The company is up 9.0% from its price of US$4.23 on 14 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$14.02 per share.Is New 90 Day High Low • Sep 24New 90-day low: US$3.43The company is down 35% from its price of US$5.28 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$18.23 per share. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Calithera Biosciences は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:CALA - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2022N/A-21-44-44N/A9/30/2022N/A-84-61-61N/A6/30/20227-85-61-60N/A3/31/202210-107-60-60N/A12/31/202110-115-66-66N/A9/30/202110-68-64-64N/A6/30/20213-80-72-72N/A3/31/2021N/A-86-79-79N/A12/31/2020N/A-90-84-84N/A9/30/2020N/A-89-80-80N/A6/30/2020N/A-87-83-83N/A3/31/2020N/A-91-85-85N/A12/31/2019N/A-90-79-79N/A9/30/2019N/A-88-74-74N/A6/30/2019N/A-86-71-71N/A3/31/201917-65-71-71N/A12/31/201822-55-65-65N/A9/30/201830-46-63-62N/A6/30/201837-33-58-57N/A3/31/201827-35-38-36N/A12/31/201726-281314N/A9/30/201719-261516N/A6/30/201711-292021N/A3/31/20174-341212N/A12/31/2016N/A-38-31-31N/A9/30/2016N/A-37N/A-32N/A6/30/2016N/A-37N/A-32N/A3/31/2016N/A-34N/A-30N/A12/31/2015N/A-33N/A-30N/A9/30/2015N/A-31N/A-24N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CALAの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: CALAの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: CALAの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: CALAの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: CALAの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CALAの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 04:53終値2026/05/19 00:00収益2022/12/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Calithera Biosciences, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Mohit BansalCitigroup IncMichael KingCitizens JMP Securities, LLCSwayampakula RamakanthH.C. Wainwright & Co.5 その他のアナリストを表示
Price Target Changed • Nov 16Price target decreased to US$12.36Down from US$30.00, the current price target is an average from 3 analysts. New target price is 419% above last closing price of US$2.38. Stock is down 88% over the past year. The company is forecast to post a net loss per share of US$5.24 next year compared to a net loss per share of US$31.16 last year.
Price Target Changed • Apr 27Price target decreased to US$2.38Down from US$2.88, the current price target is an average from 4 analysts. New target price is 850% above last closing price of US$0.25. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$0.67 next year compared to a net loss per share of US$1.56 last year.
Price Target Changed • Jan 05Price target lowered to US$10.10Down from US$11.50, the current price target is an average from 4 analysts. The new target price is 271% above the current share price of US$2.72. As of last close, the stock is down 47% over the past year.
お知らせ • Jun 15Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s DiseaseCalithera Biosciences, Inc. announced the commercial launch of its next generation system: the Cala kIQ System, the first and only FDA-cleared wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease. The Cala kIQ System delivers Cala TAPS (Transcutaneous Afferent Patterned Stimulation) therapy, which is validated by large clinical studies and real-world evidence demonstrating clinically meaningful tremor reduction and improvement in activities of daily living (ADLs). The Cala kIQ System empowers patients and physicians by providing an on-demand, comfortable, at-home therapy for ease of use and management of action hand tremors. This type of tremor occurs when the patient undergoes intentional movement or posture. Millions of people across the US live with essential tremor or Parkinson’s disease, and diagnoses continue to rise. Treatment options for these conditions have historically been medications or, in more severe cases – surgery. The Cala kIQ System with TAPS therapy offers a non-invasive, non-pharmacologic solution with minimal side effects. The Cala kIQ System measures each patient's unique tremor physiology and individualizes a stimulation pattern for tremor relief. The system is designed to be easy to use for patients and easy to manage for clinicians. Therapy is on-demand for patients and delivered via a wrist-worn wearable. Designed with patients in mind for comfort and usability, the system also offers online data insights through the MyCala.com patient portal. Patients can see their therapy session results over time and choose to share with their providers to adjust treatment plans. Cala is committed to providing patients expanded access to Cala TAPS therapy. Cala is a contracted provider with major national and regional health plans for essential tremor including both commercial and Medical Advantage members. The Cala kIQ System is covered by the Veterans Affairs (VA) Health System at no cost to VA beneficiaries. Cala is working to secure additional coverage and reimbursement for the new breakthrough designated Parkinson's disease indication for the Cala kIQ System.
お知らせ • Feb 03Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from NASDAQ Composite IndexCalithera Biosciences, Inc. will be removed from the NASDAQ Composite Index.
お知らせ • Jan 26Calithera Biosciences Board Approves Dissolution and LiquidationOn January 9, 2023, Calithera Biosciences, Inc. announced that its Board of Directors had unanimously approved the dissolution and liquidation of Calithera Biosciences pursuant to a plan of complete liquidation and dissolution, subject to stockholder approval. The company also announced, that in order to reduce costs and in connection with the planned dissolution, the company was discontinuing all clinical development programs and reducingour workforce, including the termination of most employees by the end of the first quarter. In light of planned dissolution, on January 24, 2023, the company received written notice from The Nasdaq Stock Market LLC, or Nasdaq, advising the company that based upon Nasdaq's review and pursuant to Listing Rule 5101, Nasdaq believes that the company is a public shell," and that the continued listing of the company's securities is no longer warranted. The company will not appeal Nasdaq's determination. Therefore, the company expects, based on Nasdaq's written notice, that the trading of the company's common stock will be suspended as of the opening of business on February 2, 2023, and that Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove the company's common stock from listing and registration on Nasdaq.
お知らせ • Jan 10+ 2 more updatesCalithera Biosciences, Inc. Announces Executive DeparturesCalithera Biosciences, Inc. announced that in connection with the approval of the reduction-in-force, Eric Sjogren, Ph.D. company's Senior Vice President, Drug Discovery will be leaving Calithera Biosciences on February 3, 2023. Dr. Sjogren will be entitled to certain severance payments and the continuation of health benefits pursuant to the Calithera Biosciences, Inc. In connection with the reduction-in-force and wind up of company's operations, Susan M. Molineaux, Ph.D., company's President will also be leaving Calithera Biosciences as of future date to be determined, and will be entitled to certain severance payments and the continuation of health benefits pursuant to the Calithera Biosciences, Inc.
Price Target Changed • Nov 16Price target decreased to US$12.36Down from US$30.00, the current price target is an average from 3 analysts. New target price is 419% above last closing price of US$2.38. Stock is down 88% over the past year. The company is forecast to post a net loss per share of US$5.24 next year compared to a net loss per share of US$31.16 last year.
Seeking Alpha • Oct 03Calithera gains 16% as FDA awards Fast Track status for lung cancer candidateCalithera Biosciences, Inc. (NASDAQ:CALA) added ~16% pre-market Monday after the oncology-focused biotech announced that the FDA issued the Fast Track designation for sapanisertib as a treatment for adults with a certain type of lung cancer. Specifically, the FDA has offered the designation for sapanisertib to treat adults with unresectable or metastatic squamous non-small cell lung cancer with a particular genetic mutation in tumors and who have previously received chemotherapy and immune checkpoint inhibitors. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. If certain criteria are met, such programs will also be able to win the Accelerated Approval and Priority Review, enabling the treatments to reach patients sooner. In July, CALA announced that the patient recruitment started in Phase 2 for sapanisertib (CB-228), designed to study the candidate in certain patients with squamous non-small cell lung cancer.
Seeking Alpha • Aug 29Calithera rises 8% after HC Wainwright upgrades rating to buyCalithera Biosciences (NASDAQ:CALA) is trading ~8% higher after HC Wainwright upgrades rating to Buy to Neutral, with an $8 price target. HC Wainwright analyst Swayampakula Ramakant believes the company has sufficient cash to fund operations into Q2 of 2023. The company had cash and cash equivalents of $41.8M at June 30. Calithera has two ongoing clinical development programs that are expected to provide data updates in Q1 of 2023, Ramakanth tells investors in a research note. If positive, both drugs could be evaluated in registrational studies to achieve accelerated FDA approval, says the analyst. He estimates Calithera to achieve risk-adjusted revenues of $111M by 2030. (CALA) is down ~74% YTD.
分析記事 • Aug 17Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Price Target Changed • Apr 27Price target decreased to US$2.38Down from US$2.88, the current price target is an average from 4 analysts. New target price is 850% above last closing price of US$0.25. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$0.67 next year compared to a net loss per share of US$1.56 last year.
分析記事 • Dec 17We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Recent Insider Transactions • Nov 12Independent Director recently bought US$172k worth of stockOn the 10th of November, Jonathan Drachman bought around 200k shares on-market at roughly US$0.86 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$257k more in shares than they have sold in the last 12 months.
分析記事 • Aug 27We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 03The Upcoming Calithera Cystic Fibrosis Data Could Be SignificantCalithera is guiding for the market to expect what we believe will be a key data read-out from its ongoing CB-280 study involving Cystic Fibrosis. We anticipate full data set to read out in early October at the North American Cystic Fibrosis Conference. A positive read-out here could see a very strong stock appreciation, which currently the market may be overlooking.
分析記事 • May 02Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Executive Departure • Apr 06Chief Business Officer has left the companyOn the 2nd of April, Curtis Hecht's tenure as Chief Business Officer ended after 2.2 years in the role. We don't have any record of a personal shareholding under Curtis' name. Curtis is the only executive to leave the company over the last 12 months.
分析記事 • Mar 10What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?If you want to know who really controls Calithera Biosciences, Inc. ( NASDAQ:CALA ), then you'll have to look at the...
分析記事 • Jan 17Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value EstimateIn this article we are going to estimate the intrinsic value of Calithera Biosciences, Inc. ( NASDAQ:CALA ) by taking...
Is New 90 Day High Low • Jan 05New 90-day low: US$2.72The company is down 25% from its price of US$3.61 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$23.10 per share.
Price Target Changed • Jan 05Price target lowered to US$10.10Down from US$11.50, the current price target is an average from 4 analysts. The new target price is 271% above the current share price of US$2.72. As of last close, the stock is down 47% over the past year.
分析記事 • Dec 13Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Is New 90 Day High Low • Dec 11New 90-day high: US$5.03The company is up 39% from its price of US$3.63 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$17.34 per share.
Is New 90 Day High Low • Nov 13New 90-day high: US$4.60The company is up 9.0% from its price of US$4.23 on 14 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$14.02 per share.
Is New 90 Day High Low • Sep 24New 90-day low: US$3.43The company is down 35% from its price of US$5.28 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$18.23 per share.